19 April 2023 - NICE has published evidence based recommendations on eladocagene exuparvovec (Upstaza) for the treatment of patients 18 months and over with aromatic L‑amino acid decarboxylase deficiency.

Eladocagene exuparvovec is recommended as an option for the treatment of patients 18 months and over with aromatic L‑amino acid decarboxylase (AADC) deficiency with a clinical, molecular and genetically confirmed diagnosis of AADC deficiency with a severe phenotype.

Read NICE highly specialised technologies guidance